45.6 USD
-1.3 (-2.77%)
45.6 USD
0 (0%)
COLL gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. COLL has an excellent profitability rating, but there are some minor concerns on its financial health. COLL scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make COLL a good candidate for value investing.
1. Profitability
1.1 Basic Checks
- COLL had positive earnings in the past year.
- In the past year COLL had a positive cash flow from operations.
- COLL had positive earnings in 4 of the past 5 years.
- In the past 5 years COLL always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of COLL (3.64%) is better than 83.85% of its industry peers.
- COLL's Return On Equity of 21.27% is amongst the best of the industry. COLL outperforms 91.15% of its industry peers.
- The Return On Invested Capital of COLL (9.10%) is better than 88.02% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for COLL is in line with the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
- COLL has a Profit Margin of 7.72%. This is amongst the best in the industry. COLL outperforms 82.81% of its industry peers.
- In the last couple of years the Profit Margin of COLL has declined.
- COLL has a Operating Margin of 20.74%. This is amongst the best in the industry. COLL outperforms 88.54% of its industry peers.
- In the last couple of years the Operating Margin of COLL has grown nicely.
- With a decent Gross Margin value of 57.22%, COLL is doing good in the industry, outperforming 68.75% of the companies in the same industry.
- COLL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
- COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, COLL has less shares outstanding
- COLL has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, COLL has an improved debt to assets ratio.
2.2 Solvency
- COLL has an Altman-Z score of 1.46. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of COLL (1.46) is comparable to the rest of the industry.
- COLL has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as COLL would need 2.79 years to pay back of all of its debts.
- COLL has a better Debt to FCF ratio (2.79) than 91.15% of its industry peers.
- COLL has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of COLL (2.71) is worse than 80.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.46 |
ROIC/WACC0.99
WACC9.23%
2.3 Liquidity
- COLL has a Current Ratio of 1.36. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
- COLL has a Current ratio of 1.36. This is in the lower half of the industry: COLL underperforms 74.48% of its industry peers.
- COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
- COLL has a worse Quick ratio (1.27) than 70.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
- COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.73%, which is quite impressive.
- Measured over the past years, COLL shows a very strong growth in Earnings Per Share. The EPS has been growing by 154.78% on average per year.
- Looking at the last year, COLL shows a very strong growth in Revenue. The Revenue has grown by 26.34%.
- Measured over the past years, COLL shows a quite strong growth in Revenue. The Revenue has been growing by 16.31% on average per year.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
- COLL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.58% yearly.
- COLL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.62% yearly.
EPS Next Y18.1%
EPS Next 2Y12.32%
EPS Next 3Y-0.6%
EPS Next 5Y-1.58%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y3.62%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- COLL is valuated cheaply with a Price/Earnings ratio of 6.34.
- Based on the Price/Earnings ratio, COLL is valued cheaply inside the industry as 94.79% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, COLL is valued rather cheaply.
- Based on the Price/Forward Earnings ratio of 5.60, the valuation of COLL can be described as very cheap.
- COLL's Price/Forward Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 94.27% of the companies in the same industry.
- COLL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.34 | ||
| Fwd PE | 5.6 |
4.2 Price Multiples
- 98.44% of the companies in the same industry are more expensive than COLL, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, COLL is valued cheaper than 96.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.98 | ||
| EV/EBITDA | 4.77 |
4.3 Compensation for Growth
- COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of COLL may justify a higher PE ratio.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y12.32%
EPS Next 3Y-0.6%
5. Dividend
5.1 Amount
- No dividends for COLL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
45.6
-1.3 (-2.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners120.33%
Inst Owner Change1.05%
Ins Owners1.42%
Ins Owner Change-0.82%
Market Cap1.44B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.67
Price Target54.23 (18.93%)
Short Float %17.23%
Short Ratio10.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)13.6%
PT rev (3m)19.21%
EPS NQ rev (1m)-3.66%
EPS NQ rev (3m)3.93%
EPS NY rev (1m)-0.9%
EPS NY rev (3m)-9.58%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)3.24%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)3.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.34 | ||
| Fwd PE | 5.6 | ||
| P/S | 1.9 | ||
| P/FCF | 4.98 | ||
| P/OCF | 4.95 | ||
| P/B | 5.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.77 |
EPS(TTM)7.19
EY15.77%
EPS(NY)8.14
Fwd EY17.85%
FCF(TTM)9.15
FCFY20.07%
OCF(TTM)9.2
OCFY20.18%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.35
PEG (5Y)N/A
Graham Number37.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.46 |
F-Score7
WACC9.23%
ROIC/WACC0.99
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y18.1%
EPS Next 2Y12.32%
EPS Next 3Y-0.6%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year154.57%
EBIT Next 3Y23.61%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
What is the valuation status for COLL stock?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.